FDA conditionally approves drug for canine neuropathic painMay 13, 2026Liavium-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. The drug, with the active ingredient pregabalin, reduces the release of neurotransmitters that send pain signals in the spinal cord.
Education Center - SponsoredIntegrating Therapeutic Nutrition for Chronic Allergiesby • Hill's Pet NutritionIntended for veterinary audiences
